Initial testing (Stage 1) of the antibody-maytansinoid conjugate, IMGN901 (Lorvotuzumab mertansine), by the pediatric preclinical testing program

Pediatric Blood and Cancer

Volumn 60, Issue 11, 2013, Pages 1860-1867

  Wood, Andrew C ^a   Maris, John M ^a   Gorlick, Richard ^b   Kolb, E Anders ^c   Keir, Stephen T ^d   Reynolds, C Patrick ^e   Kang, Min H ^e   Wu, Jianrong ^f   Kurmasheva, Raushan T ^g   Whiteman, Kathleen ^h   Houghton, Peter J ^g   Smith, Malcolm A ⁱ  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b CHILDREN S HOSPITAL AT MONTEFIORE   (United States)

^c NEMOURS ALFRED I DUPONT HOSPITAL FOR CHILDREN   (United States)

^d DUKE UNIVERSITY MEDICAL CENTER   (United States)

^e TEXAS TECH UNIVERSITY HEALTH SCIENCES CENTER   (United States)

^f ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

^g NATIONWIDE CHILDREN S HOSPITAL   (United States)

^h IMMUNOGEN INC   (United States)

ⁱ NATIONAL CANCER INSTITUTE   (United States)

Author keywords

Antibody maytansinoid conjugate; Developmental therapeutics; Microtubules; Preclinical testing

Indexed keywords

CD56 ANTIGEN; LORVOTUZUMAB MERTANSINE; TOPOTECAN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIGEN EXPRESSION; ARTICLE; CANCER INHIBITION; CONTROLLED STUDY; EPENDYMOMA; FEMALE; IN VITRO STUDY; IN VIVO STUDY; MEDULLOBLASTOMA; MOUSE; NEUROBLASTOMA; NEUROBLASTOMA CELL; NONHUMAN; OSTEOSARCOMA; PRIORITY JOURNAL; RHABDOMYOSARCOMA; SOLID TUMOR; XENOGRAFT;

ANTIBODY-MAYTANSINOID CONJUGATE; DEVELOPMENTAL THERAPEUTICS; MICROTUBULES; PRECLINICAL TESTING;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; DRUG SCREENING ASSAYS, ANTITUMOR; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; MAYTANSINE; MICE; MICE, SCID; NEOPLASMS, EXPERIMENTAL; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84883802876     PISSN: 15455009     EISSN: 15455017     Source Type: Journal    
DOI: 10.1002/pbc.24647     Document Type: Article

References (44)

1. Erickson HK, Lambert JM. ADME of antibody-maytansinoid conjugates. AAPS J 2012; 14:799-805.
2. Issell BF, Crooke ST. Maytansine. Cancer Treat Rev 1978; 5:199-207.
3. Lutz RJ, Whiteman KR. Antibody-maytansinoid conjugates for the treatment of myeloma. mAbs 2009; 1:548-551.
4. Ishitsuka K, Jimi S, Goldmacher VS, et al. Targeting CD56 by the maytansinoid immunoconjugate IMGN901 (huN901-DM1): A potential therapeutic modality implication against natural killer/T cell malignancy. Br J Haematol 2008; 141:129-131.
5. Chari RV. Targeted cancer therapy: Conferring specificity to cytotoxic drugs. Acc Chem Res 2008; 41:98-107.
6. Chari RV, Martell BA, Gross JL, et al. Immunoconjugates containing novel maytansinoids: Promising anticancer drugs. Cancer Res 1992; 52:127-131.
7. Remillard S, Rebhun LI, Howie GA, et al. Antimitotic activity of the potent tumor inhibitor maytansine. Science 1975; 189:1002-1005.
8. Eagan RT, Creagan ET, Ingle JN, et al. Phase II evaluation of maytansine in patients with metastatic lung cancer. Cancer Treat Rep 1978; 62:1577-1579.
9. Blum RH, Kahlert T. Maytansine: A phase I study of an ansa macrolide with antitumor activity. Cancer Treat Rep 1978; 62:435-438.
10. Chabner BA, Levine AS, Johnson BL, et al. Initial clinical trials of maytansine, an antitumor plant alkaloid. Cancer Treat Rep 1978; 62:429-433.
11. Cabanillas F, Rodriguez V, Hall SW, et al. Phase I study of maytansine using a 3-day schedule. Cancer Treat Rep 1978; 62:425-428.
12. Liu C, Tadayoni BM, Bourret LA, et al. Eradication of large colon tumor xenografts by targeted delivery of maytansinoids. Proc Natl Acad Sci USA 1996; 93:8618-8623.
13. Liu C, Chari RV. The development of antibody delivery systems to target cancer with highly potent maytansinoids. Expert Opin Invest Drugs 1997; 6:169-172.
14. LoRusso PM, Weiss D, Guardino E, et al. Trastuzumab emtansine: A unique antibody-drug conjugate in development for human epidermal growth factor receptor 2-positive cancer. Clin Cancer Res 2011; 17:6437-6447.
15. Blackwell KL, Miles D, Gianni L, et al. Primary results from EMILIA, a phase III study of trastuzumab emtansine (T-DM1) versus capecitabine (X) and lapatinib (L) in HER2-positive locally advanced or metastatic breast cancer (MBC) previously treated with trastuzumab (T) and a taxane. J Clin Oncol 2012; 30: (suppl; abstr LBA1).
16. Thiery JP, Duband JL, Rutishauser U, et al. Cell adhesion molecules in early chicken embryogenesis. Proc Natl Acad Sci USA 1982; 79:6737-6741.
17. Prag S, Lepekhin EA, Kolkova K, et al. NCAM regulates cell motility. J Cell Sci 2002; 115:283-292.
18. Akeson RA, Wujek JR, Roe S, et al. Smooth muscle cells transiently express NCAM. Brain Res 1988; 464:107-120.
19. Jensen M, Berthold F. Targeting the neural cell adhesion molecule in cancer. Cancer Lett 2007; 258:9-21.
20. Cole GJ, Loewy A, Glaser L. Neuronal cell-cell adhesion depends on interactions of N-CAM with heparin-like molecules. Nature 1986; 320:445-447.
21. Koros AM. Neuroendocrine markers expressed by human natural killer (NK) cells are also detectable on human small cell carcinomas, neuroblastomas, and sea urchin coelomocytes. Int J Neurosci 1990; 51:255-256.
22. Van Camp B, Durie BG, Spier C, et al. Plasma cells in multiple myeloma express a natural killer cell-associated antigen: CD56 (NKH-1; Leu-19). Blood 1990; 76:377-382.
23. McCluggage WG, McKenna M, McBride HA. CD56 is a sensitive and diagnostically useful immunohistochemical marker of ovarian sex cord-stromal tumors. Int J Gynecol Pathol 2007; 26:322-327.
24. Kurokawa M, Nabeshima K, Akiyama Y, et al. CD56: A useful marker for diagnosing Merkel cell carcinoma. J Dermatol Sci 2003; 31:219-224.
25. Bourne SP, Patel K, Walsh F, et al. A monoclonal antibody (ERIC-1), raised against retinoblastoma, that recognizes the neural cell adhesion molecule (NCAM) expressed on brain and tumours arising from the neuroectoderm. J Neurooncol 1991; 10:111-119.
26. Mechtersheimer G, Staudter M, Moller P. Expression of the natural killer cell-associated antigens CD56 and CD57 in human neural and striated muscle cells and in their tumors. Cancer Res 1991; 51:1300-1307.
27. Molenaar WM, Muntinghe FL. Expression of neural cell adhesion molecules and neurofilament protein isoforms in Ewing's sarcoma of bone and soft tissue sarcomas other than rhabdomyosarcoma. Hum Pathol 1999; 30:1207-1212.
28. Ikushima S, Yoshihara T, Matsumura T, et al. Expression of CD56/NCAM on hematopoietic malignant cells. A useful marker for acute monocytic and megakaryocytic leukemias. Int J Hematol 1991; 54:395-403.
29. Winter C, Pawel B, Seiser E, et al. Neural cell adhesion molecule (NCAM) isoform expression is associated with neuroblastoma differentiation status. Pediatr Blood Cancer 2008; 51:10-16.
30. Thompson J, George EO, Poquette CA, et al. Synergy of topotecan in combination with vincristine for treatment of pediatric solid tumor xenografts. Clin Cancer Res 1999; 5:3617-3631.
31. Frgala T, Kalous O, Proffitt RT, et al. A fluorescence microplate cytotoxicity assay with a 4-log dynamic range that identifies synergistic drug combinations. Mol Cancer Ther 2007; 6:886-897.
32. Kang MH, Smith MA, Morton CL, et al. National Cancer Institute Pediatric Preclinical Testing Program: Model description for in vitro cytotoxicity testing. Pediatr Blood Cancer 2011; 56:239-249.
33. Sebaugh JL. Guidelines for accurate EC50/IC50 estimation. Pharmaceut Statist 2011; 10:128-134.
34. Houghton PJ, Morton CL, Tucker C, et al. The pediatric preclinical testing program: Description of models and early testing results. Pediatr Blood Cancer 2007; 49:928-940.
35. Houghton PJ, Morton CL, Gorlick R, et al. Stage 2 combination testing of rapamycin with cytotoxic agents by the Pediatric preclinical testing program. Mol Cancer Therap 2010; 9:101-112.
36. Pappo AS, Lyden E, Breitfeld P, et al. Two consecutive phase II window trials of irinotecan alone or in combination with vincristine for the treatment of metastatic rhabdomyosarcoma: The Children's Oncology Group. J Clin Oncol Am Soc Clin Oncol 2007; 25:362-369.
37. Houghton PJ, Morton CL, Tucker C, et al. The Pediatric preclinical testing program: Description of models and early testing results. Pediatr Blood Cancer 2007; 49:928-940.
38. Carol H, Houghton PJ, Morton CL, et al. Initial testing of topotecan by the pediatric preclinical testing program. Pediatr Blood Cancer 2010; 54:707-715.
39. Woll PJ, Lorigan P, O'Brien M, et al. Clinical experience of IMGN901 (BB-10901, huN901-DM1) in patients with merkel cell carcinoma (MCC). Mol Cancer Therap 2009; 8: (Supplement 1)(12):Abstr #B237.
40. Woll PJ, Moore KN, Bhatia S, et al. Efficacy results from a phase I study of lorvotuzumab mertansine (IMGN901) in patients with CD56-positive solid tumors. J Clin Oncol 2011; 29: (suppl; abstr e13582).
41. Whiteman K, Murphy M, Cohan KP, et al. Preclinical evaluation of IMGN901 (huN901-DM1) as a potential therapeutic for ovarian cancer. 99th AACR Annual Meeting. 2008; Abstr #2135.
42. Erickson HK, Widdison WC, Mayo MF, et al. Tumor delivery and in vivo processing of disulfide-linked and thioether-linked antibody-maytansinoid conjugates. Bioconjug Chem 2010; 21:84-92.
43. Lewis Phillips GD Li G, Dugger DL, et al. Targeting HER2-positive breast cancer with trastuzumab-DM1, an antibody-cytotoxic drug conjugate. Cancer Res 2008; 68:9280-9290.
44. Pode-Shakked N, Shukrun R, Mark-Danieli M, et al. The isolation and characterization of renal cancer initiating cells from human Wilms' tumour xenografts unveils new therapeutic targets. Embo Mol Med 2013; 5:18-37.